Journal
MARINE DRUGS
Volume 19, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/md19020079
Keywords
Streptoglutarimide H; lung cancer cells; antiproliferative activity; cell cycle block; glycolysis; USP28; c-Myc
Categories
Funding
- National Key R&D Program of China [81773587]
- [2018YFC0310600]
Ask authors/readers for more resources
Streptoglutarimide H (SGH) was identified as a new glutarimide from marine-derived actinomycete with in vitro antiglioma activity. SGH was found to significantly inhibit lung cancer cell proliferation by downregulating cell cycle-related proteins, glycolytic enzymes, and important cancer transcription factors. The potent anticancer activity and multiple mechanisms suggest SGH as a novel antitumor compound against lung cancer cells.
In 2019, streptoglutarimide H (SGH) was characterized as a new glutarimide from the secondary metabolites produced by a marine-derived actinomycete Streptomyces sp. ZZ741 and shown to have in vitro antiglioma activity. However, the antiproliferative activity and potential mechanism of SGH against lung cancer cells have not yet been characterized. This study demonstrated that SGH significantly inhibited the proliferation of different lung cancer cells. In terms of mechanism of action, SGH downregulated cell cycle- and nucleotide synthesis-related proteins to block cell cycle at G0/G1 phase, reduced the expression levels of glycolytic metabolic enzymes to inhibit glycolysis, and downregulated the important cancer transcription factor c-Myc and the therapeutic target deubiquitinase USP28. Potent anticancer activity and multiple mechanisms indicated SGH to be a novel antitumor compound against lung cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available